The University of Virginia has begun screening ACC patients with progressive disease for a new clinical trial. Supported by Novartis Pharmaceuticals, the Phase II study will enroll 10 patients to determine the efficacy and safety of the oral drug Dovitinib, an inhibitor of FGFR, VEGFR and PDGFR.
The National Institute of Dental and Craniofacial Research (NIDCR) posted two Requests for Applications (RFAs) seeking grant proposals to enhance basic and translational research on salivary gland tumors (SGTs). This anticipated commitment of approximately $8 million over the next four years underscores the continuing strong leadership of NIDCR in this under-studied field.
Your support made 2011 a banner year! And together we can do even more in 2012! Your generosity and the deep commitment of our affiliated researchers have allowed us to reach some crucial milestones and chart the path forward for more successes.
ACC Patients with tumors that are clearly growing face a journey with few signposts. This update provides information on treatment options including radiation, tumor profiling and clinical trials.
ACC patients dealing with progressive disease face many uncertainties. This guide for patients and physicians provides context and information for decisions about clinical trials.
ACCRF and ACCOI conducted a joint survey of the ACC patient community to gauge the priorities, communication preferences and volunteering interests of survivors, families, friends and physicians. The response was dramatic and the organizations are coordinating to meet the needs of the community.
The pace of research progress in ACC has quickened over the past two years, providing the patient community with justifiable hope for improved outcomes in the coming years. Here we review some of the most significant advances as well as key goals for the remainder of this year.
ACCRF convened a meeting of its Scientific Advisors to review recent research findings and to explore the implications of the fusion gene´s discovery for the Research Agenda.
The National Institute of Dental and Craniofacial Research (NIDCR) has moved forcefully to address salivary gland tumors, allocating over $12 million to research projects.
Philanthropists Irwin and Joan Jacobs make a major gift to ACCRF.